Oncotelic Therapeutics to undergo significant fair-value remeasurement of GMP Bio stake.

Oncotelic Therapeutics Inc. is preparing for a significant fair-value remeasurement of its 45% stake in joint venture GMP Bio, driven by a new independent valuation indicating a potential step-up in asset value. This shift strengthens Oncotelic Therapeutics' position in the oncology space, making it a key player alongside other innovative leaders like IO Biotech Inc. and Novartis AG. The remeasurement under US GAAP will provide a clearer picture of the company's scientific and commercial progress.